Johnson & Johnson Elevates Cardiac Ablation with VARIPULSE Pro in Europe

Johnson & Johnson has announced the European launch of VARIPULSE Pro following CE Mark approval, marking a significant advancement in its pulsed field ablation portfolio. The new system is developed based on the proven VARIPULSE Platform, but it features a more advanced pulse sequence. This aimed at reducing the efficiency of the procedures but with a robust safety and effectiveness profile. VARIPULSE Pro is one milestone that indicates that the company is still advancing in innovation within electrophysiology. 

Advancing Ablation Technology for Faster and More Precise Procedures

VARIPULSE Pro, a next-generation pulse sequence, is engineered to deliver ablation significantly faster than previous iterations. The system is capable of achieving the same results with a lesion with approximately five times the speed of the procedures, with a reduction in overall treatment time. This development is accompanied by the reduced temperature profile. They ensure the existence of safer energy delivery and reduce the possible thermal damage of tissues around the site.

According to Michael Bodner, Company Group Chair of Electrophysiology and Neurovascular at Johnson & Johnson MedTech, it marks the beginning of continued innovation in the area of pulsed field ablation technologies, as VARIPULSE Pro helps physicians achieve greater efficiency in their procedures and enhances the quality of delivered care and patient outcomes.

According to Precedence Research, the Atrial Fibrillation Surgery Market size was calculated at USD 8.30 billion in 2025 and is predicted to increase from USD 8.91 billion in 2026 to approximately USD 16.95 billion by 2035, expanding at a CAGR of 7.40% from 2026 to 2035. The market growth is attributed to rising atrial fibrillation prevalence, aging populations, and rapid adoption of advanced catheter and surgical ablation technologies.

Industry Impact and Future Outlook

The introduction of VARIPULSE Pro comes at a time when the global burden of cardiac arrhythmias is rising rapidly. The World Health Organization reports that cardiovascular diseases are one of the major causes of death in the world, and atrial fibrillation. 
There is a growing need to find effective and minimally invasive methods of their treatment, with the ever-increasing prevalence of this condition. Furthermore, companies' development of pulsed field ablation is likely to contribute to evolving electrophysiology.